Drug Profile
Research programme: peptide therapeutics for cancer - Bristol-Myers Squibb/PeptiDream
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer